patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

FDA lifts clinical hold on Sanofi’s haemophilia drug

The company recently abandoned one of its gene-silencing drugs – revusiran for the rare disease hereditary ATTR amyloidosis with cardiomyopathy – although its new lead program patisiran for ATTR plus polyneuropathy remains ... Patisiran – also

Latest news

Alnylam takes off on APOLLO trial results

APOLLO showed that Alnylam's lead RNAi therapy patisiran is effective as a treatment for the rare disorder hereditary ATTR amyloidosis with polyneuropathy , and critically was well-tolerated by patients, sparking ... Patisiran also improved secondary
Ionis says rare disease drug works, but safety concerns linger

Investors were spooked by the risks and Ionis shares declined 11%, while rival Alnylam - which is expecting phase III results for its FAP therapy patisiran in the coming months - rose 13%. ... Alnylam dropped lead amyloidosis drug revusiran last year
Alnylam pulls lead drug revusiran after deaths in phase III trial

Shares in the company fell more than 40% yesterday as news of the setback emerged, and Alnylam will now have to concentrate its efforts on patisiran, another RNAi drug in phase ... On a conference call, Alnylam's chief medical officer Akshay Vaishnaw
Genzyme opts into gene silencing therapy for haemophilia

ALN-AT3 is the first opt-in since the 2014 rare disease alliance was formed, but the third opt-in overall as Genzyme has previously taken licenses to revusiran and patisiran,
mRNA - message received

lead candidate patisiran, a treatment for rare disease familial amyloidotic polyneuropathy.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch table for January 2014

Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.
Pharma deals during January 2014

The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Manager – Med Comms – London: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Programme Executive: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and bebefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Medical Writer - (London, Brighton or Copenhagen): Competitive

Scientific Director: Great salary and bebefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager / Account Director: Great salary and bebefits

Senior Medical Writer: Great salary and benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Subscribe to our email news alerts

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...